PNH in Focus: Neepaja Canjiradan Discusses Hemolysis, Diagnostic Clues, and Complement Inhibitor Therapy
Neepaja Canjiradan, a clinical pathologist at AVM Labs, posted on LinkedIn:
”Haematology series 17
Paroxysmal nocturnal Haemoglobinuria: The only condition where your urine says “Good Morning” darker than your coffee
On the Peripheral Smear
Hemolysis galore → bite cells, ghost cells, and the occasional schistocyte cameo.
Reticulocytosis – marrow working overtime like a resident on night duty.
Basically looks like “aftermath of a complement bar fight.”
In the Bone Marrow
Hypoplastic/aplastic in some, hyperplastic in others.
Erythroid hyperplasia = marrow screaming “I got this!” while clearly not.
Frequently hand-in-hand with aplastic anemia or MDS-PNH is never lonely.
Flow Cytometry (the Real MVP)
The mic-drop moment → loss of CD55 and CD59 on RBCs and granulocytes.
Forget the Ham test—flow cytometry is the Sherlock Holmes here.
Seeing that PNH clone pop up is equal parts diagnostic thrill and clinical reality check.
Treatment in a Nutshell
Big strides from IV infusions to oral therapies.
Complement inhibitors galore, but let the hematologists juggle the alphabet soup.
HSCT = still the only curative pathway.
Pathologist’s Humor Corner
PNH patients: “Why is my urine so dark in the morning?”
Pathologist: “Because your RBCs had a rough night.”
RBCs without CD55/CD59 → the ultimate example of what happens when you skip PPE.
Flow cytometry in PNH = Facebook relationship status: “It’s complicated.”
Bottom Line
Smear gives the clues,
Marrow shows the struggle,
Flow cytometry seals the deal.
PNH may be rare, but it keeps pathology exciting – diagnostics with just the right mix of science and sass.”
Stay updated with Hemostasis Today.
-
Nov 4, 2025, 09:26Courtney Lawrence: One of Our Most Popular American Red Cross SUCCESS Talks is Just Around the Corner!
-
Nov 4, 2025, 09:21New Study by Emmanuel J Favaloro and Team Questions Consistency in APS Classification and Diagnosis
-
Nov 4, 2025, 09:20Yazan Abou Ismail to Present Insights on AI Models in TTP at 67th ASH Annual Meeting
-
Nov 4, 2025, 09:17David Calvet Canut on Takeda's HyHub: A Shift Toward Patient-Centered Biologics
-
Nov 4, 2025, 09:16Samantha Nelson Encourages You to Share Your Experience on World Thrombosis Day
-
Nov 4, 2025, 08:57Toluwalase Awoyemi: Digital Health Meets Maternal Heart Care
-
Nov 4, 2025, 08:53Rebecca Ahrens Nicklas Shares FDA Interactions on Interventional Genetics with The Rare Disease Community
-
Nov 3, 2025, 09:13Claudio Carrubba on How Timing Truly Matters in Trauma Embolization
-
Nov 3, 2025, 08:57Multiplex Apolipoprotein Panel Boosts Cardiovascular Risk Prediction and Precision Therapy
-
Nov 3, 2025, 08:46Rachel Lamerton and Colleagues on Activation of Platelets in Flow Cytometry
-
Nov 4, 2025, 09:10OCCUPI Trial Analysis Highlights Benefits of OCT Guidance in ACS Patients
-
Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Nov 4, 2025, 09:17HaemophiliaIRL Series Begins․ Advances in von Willebrand Disease Treatment
-
Nov 4, 2025, 09:14Exploring Molecular Pathways of Aging in Hematopoiesis․ FEBS Workshop 2025
-
Nov 4, 2025, 08:28Fritz Roth Thanks Supporters of Science Magazine Study Linking Genes to High Cholesterol and Heart Attack Risk
-
Nov 4, 2025, 08:22Colleen Silk on Novo Nordisk Taking the 2025 Prix Galien US Award
-
Nov 4, 2025, 08:14Cristina Anton: Excited to Be Part of Women in Hematology!